ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSᵃⁱ™ Technology. The 2024 Impact Award, sponsored by InterSystems , acknowledges BioStrand’s innovative LENSᵃⁱ technology, selected from over 1,000 client

Tech update! Tune in to Jennifer Bath and Radius Research discussing the innovative LENSᵃⁱ™ Integrated Intelligence Platform API by BioStrand (IPA subsidiary). This game-changing API plugs directly into large pharma or biotech existing platforms, transforming their ability to

IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Partnership to Develop First-In-Class AI Model for Pharmacogenomic Recommendations Using LENSᵃⁱ™ "With more genomic data and new pharmacogenetic insights, more advanced methods are urgently needed to analyze and predict

ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer. Ms. Taylor is a seasoned financial executive with extensive experience in both early-stage and large growth companies, including those privately held, private equity-backed, and publicly listed. She has a strong

Mark your calendars for the upcoming Q4 and fiscal year end 2024 earnings conference call. Join us July 25, 2024, at 10:30am EST for an update on quarterly results with key insights on strategic and forward progress. Participant Dial-In Details: Participants call one of the

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Business Updates for Fourth Quarter and Full Fiscal Year 2024 • Achieves Record $24.5 Million Revenue in FY 2024, Showcases Cutting-Edge Technological Advancements Making strides in strategic initiatives: • Expands

Press Release: ImmunoPrecise Antibodies successfully engineers in silico antibodies to elusive tumor protein using its patented LENSᵃⁱ™ technology. "This marks a noteworthy milestone for the biotechnology industry, demonstrating LENSᵃⁱ's ability to engineer highly specific

IPA to participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York, September 9-11. The company's management team invites shareholders and all interested parties to attend. The Global Investment Conference brings together companies, industry

Mark your calendars for the upcoming Q1 2025 earnings conference call. Join us Sept. 16, 2024, at 10:30am EST for an update on quarterly results with key insights on strategic and forward progress. Participant Dial-In Details Participants call one of the allocated dial-in

IPA announces Q1 2025 results: "Our commitment to end-to-end in silico engineering of antibodies for challenging targets has delivered exceptional results. By harnessing our advanced computational capabilities, we've not only accelerated our R&D process but also significantly

Press Release: ImmunoPrecise Antibodies advances therapeutic innovation with groundbreaking rabbit antibody developments. Rabbit B Cell Select® drives OncoResponse’s clinical breakthrough in cancer treatment. In a live presentation at the recent PEGS 2024 conference,

Catch Dr. Jennifer Bath's insightful Nasdaq interview with Jane King and Ari Zoldan, airing Saturday, September 28th! Dr. Bath explores how unlocking the full potential of integrated data and AI analytics is aimed at revolutionizing therapeutics research, enhancing patient

Press Release: ImmunoPrecise Antibodies subsidiary signs material transfer agreement with Biotheus. Talem Therapeutics' antibody asset to be evaluated for bispecific development against solid tumors. "We are happy to enter into a collaboration with ImmunoPrecise Antibodies, a